Research Article

Geet P. Asnani*, Chandrakant R. Kokare

In vitro and in vivo evaluation of colon cancer targeted epichlorohydrin crosslinked Portulaca-alginate beads

https://doi.org/10.1515/bmc-2018-0019
received October 5, 2018; accepted December 3, 2018.

Abstract: The aim of this study was to formulate a novel dual crosslinked hydrogel bead using Portulaca mucilage for colon-targeted delivery of 5-fluorouracil (5-FU) and evaluate its safety, specificity and efficacy. The ionotropic gelation technique was employed to prepare the hydrogel beads of Portulaca mucilage. For this, the mucilage was initially crosslinked with alginate and calcium ions. Epichlorohydrin was employed as a crosslinker in the second crosslinking step. The formulation was subjected to in vitro and in vivo studies to evaluate morphology, size, cytotoxicity, and organ distribution. Human HT-29 colon cancer cell-line was used for in vitro assays and in vivo studies were performed in Wistar rats to assess the usefulness and effectiveness of the formulation for colon cancer therapy. Microsphere sizes ranged from 930 to 977μm and possessed a high level of drug encapsulation efficiency (ca. 78% w/w). Compared with 5-FU solution (Tmax = 1.2 h, mean resident time: MRT = 3.3h) the dual crosslinked Portulaca microspheres exhibited sustained drug release after oral administration to rats (Tmax = 16h, MRT = 14h). The relative bioavailability of 5-FU solution and the microspheres were 100 and 93.6% respectively. Tissue distribution studies indicated high concentration of 5-FU in colon. In-vitro anticancer assay demonstrated IC50 value of 11.50 μg/ml against HT-29 colon cancer cell line. The epichlorohydrin cross-linked Portulaca microspheres prepared in this study provided sustained release of 5-FU up to 16h in the colonic region and enhanced the antitumor activity of the neoplastic drug. The formulation is hence an ideal carrier system for colon-targeted drug delivery.

Keywords: Portulaca oleracea; mucilage; natural polysaccharide; colon targeting; 5-fluorouracil; beads; ionotropic gelation.

Introduction

The second largest non-communicable disease is cancer – a devastating illness that continues to cause morbidity and mortality worldwide. Patients suffering from different malignancies, including colorectal cancer, are treated with chemotherapy [1, 2]. One of the generally employed chemotherapeutic agents is 5-fluorouracil (5-FU), which is employed in this study as a model water-soluble antineoplastic drug. As a pyrimidine antimetabolite, 5-FU is the most widely used anticancer agent known to act by inhibiting thymidylate synthase [3, 4]. Currently, 5-FU is being given to patients predominantly by the intravenous (i.v.) route of drug administration although oral administration is widely preferred over i.v. treatment due to its patient compliance. However, when given orally, the drug has problems of erratic absorption, inconsistent dosing and side effects [5, 6]. In addition, the half-life of 5-FU in plasma is only 10–20min, and as such high doses (up to 600 mg/m² weekly) have to be administered to reach therapeutic drug levels [7, 8]. Previous reports suggest that due to random distribution in tumor and healthy tissues, 5-FU induced toxic side effects in the gastrointestinal tract and bone marrow [9]. It has also resulted in myelotoxicity and stomatitis [10], gut mucosa toxicity [11] and severe neurotoxicity reactions in the brain [12]. Consequently, it is crucial to find efficient targeting strategies to enhance bioavailability, decrease the required dose and protect healthy tissues from harmful side effects. To meet...
this objective, different 5-FU dosage forms have been formulated, which include transdermal patch [13] and water in oil emulsions [14]. Furthermore, different research groups have been trying to increase the therapeutic efficacy of 5-FU and reduce its side effects by employing vesicular phospholipid gels [15], nanoliposomes [16] and tocosome technology [17] and optimizations particularly with respect of safety and stability concerns are ongoing.

In the case of addressing colon cancer, numerous methods have been reported to target drugs to colon. These include prodrugs, pH-responsive strategies, sustained-release formulations, microbial-activated systems, and intestinal-pressure colon delivery capsules [18-21]. The wide pH range of gastro intestinal (GI) tract poses a challenge to the delivery of therapeutic agents to the colon. Many enteric coating techniques have been attempted thus far to address problems associated with drug delivery to colon [22-26]. In the present research, Portulaca (Purslane) is used as an oral delivery matrix for targeting 5-FU to the colon. It is a novel source of natural polysaccharide, which is soluble or swellable in acidic pH environments while it does not swell in neutral or alkaline pH media. pH independent swelling characteristic was imparted to Portulaca by cross-linking with sodium alginate followed by dual crosslinking with epichlorohydrin to prolong the release of 5-FU in vivo. Such cross-linking with epichlorohydrin has several inherent advantages as it is biocompatible and is devoid of toxic side effects [27].

Microspheres crosslinked with epichlorohydrin are among the most efficient drug delivery systems which can be used for targeting 5-FU to colon cancer. These formulations were manufactured through ionotropic gelation technique [28]. Hydrophilic crosslinked polymer beads were prepared using sodium alginate and Portulaca mucilage (PM), which was extracted from the leaves of Purslane (of the plant family Portulacaceae). This natural mucilage can be a potential excipient to overcome the issues of biocompatibility and biodegradability. Moreover, the polysaccharides present in the mucilage of the leaves can be modified with the aim of adapting their physicochemical properties towards targeting ability, improved loading capacity, stability and scalability. However, the hydrophilic and swelling behavior of PM results in unpredicted drug release from the microspheres. In order to address this issue, epichlorohydrin was utilized in order to control the release of 5-FU specifically in the colon. Epichlorohydrin is known as bifunctional alkylating agent and is being used in the formulation of drug carrier systems composed of mucilages [29-31].

Portulaca Mucilage is hydrophilic in nature and is capable of increasing the drug entrapment efficiency of the microbeads. It is hypothesized that the hydrophilic polysaccharide-based crosslinked particulate drug carriers such as beads have the advantages that they pass uniformly through the gastrointestinal tract with a predictable release profile [32]. In the present study, 5-FU-loaded beads were prepared using a hydrophilic polymer matrix containing a mixture of the two polysaccharides. Sodium alginate, a linear polysaccharide isolated from seaweed, is composed of oxidized sugar units joined together to form an ionic polymer [33]. The presence of negatively charged –COOH side chains and –OH groups make this natural polysaccharide extremely hydrophilic. Replacing the sodium ions of sodium alginate with calcium ions leads to cross-linking between the polymer chains and consequently results in the formation of an insoluble gel i.e. calcium alginate [33]. Recently, it has been reported that single crosslinked formulations show premature drug release [34]. Consequently, in order to extend the release of drug in the colon the single crosslinked beads were crosslinked again using epichlorohydrin (a bifunctional alkylating agent). The freely available –COOH and –OH functional groups in the Portulaca mucilage act as crosslinking sites and can form diether linkages with epichlorohydrin thus forming stable beads, which are dual crosslinked with epichlorohydrin. The microsphere formulations were characterized in terms of their morphology and particle size by using SEM technique. In vitro cytotoxicity of the formulations was assessed using the Human colon cancer cell-line (HT-29). In vivo pharmacokinetic evaluations were performed in Wistar rats to understand the effectiveness of the formulated hydrogel beads for colon cancer therapy.

Materials And Methods

Materials

Fresh leaves of Portulaca oleracea (Purslane) were collected from Phursungi Village (Pune, India) in the month of June. The anticancer drug 5-FU was purchased from Sigma Aldrich Co. (USA). Sodium alginate (90-180 molecular weight = 216.121) was procured from S.D. Fines (Mumbai, India). Epichlorohydrin and calcium chloride were purchased from Sigma Chem. Ltd. (New Delhi, India). Solvents, i.e. ethanol and acetone, were of analytical grade and product of Merck Ltd. Co. (India).
Isolation of mucilage

A quantity of 1kg of Portulaca oleracea (Purslane) leaves were weighed and then dried at 40°C. Dried leaves were powdered using a blender and then boiled in 1L of dH₂O at 100°C while stirring to form a slurry. The slurry was cooled and filtered using a muslin cloth and kept in refrigerator (4°C) for a 12-hour period. The obtained solution was decanted and then boiled to decrease the volume to half and afterwards left to cool down at room temperature.

In the next stage, acetone was poured on the obtained solution for three times to assist the precipitation of the mucilage, which was then air dried at room temperature for 24 hours. The dried flakes obtained at this stage were then grinded to fine powder and stored in an airtight container until further use.

Preparation of single crosslinked Portulaca-alginate hydrogel beads

For the preparation of single-crosslinked hydrogel beads, encapsulating 5-FU, the simple ionotropic gelation technique was employed [35]. The process involved crosslinking of sodium alginate and Portulaca mucilage by the mediation of calcium ions (using 3% aqueous solution of calcium chloride). The mixing ratio of sodium alginate and Portulaca mucilage was 2.0:1.0 (w/w). A blend of the polymeric solution (containing mixture of sodium alginate and Portulaca mucilage) was prepared in 100ml volume using distilled water (dH₂O). The water-soluble anticancer drug 5-FU (1% w/v) was added to the polymeric solution and the mixture was stirred at 500rpm for 1 hour using a magnetic stirrer at room temperature. The resultant solution was bath sonicated, in order to remove gas bubbles, and was then dropped from a 23G needle at a 5cm height into calcium chloride solution (2% w/v). The hydrogel beads were obtained and excess calcium chloride was removed by washing with dH₂O and air dried overnight at 30°C according to a previously reported procedure [36].

Preparation of double crosslinked Portulaca–alginate hydrogel beads

Double crosslinked hydrogel beads were prepared as follows: the single crosslinked hydrogel beads, in their wet state, prepared in the previous stage, were immersed into 100ml sodium hydroxide solution (2 N) and stirred gently at 40°C for 1.5 hours. Then, 10gr epichlorohydrin was added and the beads were stirred at ca. 20rpm for 24 hours at room temperature. Epichlorohydrin is known as a bifunctional alkylating agent [29-31], and was employed in the formulation as a second crosslinking agent. The hydrogel beads obtained at this stage were in the semisolid state. The hydrogel beads were collected and air-dried overnight at 30°C as explained by Awasthi and co-workers [37].

Determination of encapsulation efficiency and percentage yield

The double-crosslinked hydrogel beads were accurately weighed (equivalent to 100mg of 5-FU), powdered and were then bath sonicated in 250ml of phosphate buffer (pH 7.4). The solution obtained was passed through 0.45μm membrane filters. After performing appropriate dilutions, the content of the filtrate was determined using a UV-Vis spectrophotometer (Shimadzu-1800, Japan), by measuring the absorbance of 5-FU at 266nm in comparison to the constructed calibration curves. The percentage yield of hydrogel bead manufacture and drug encapsulation efficiency (i.e. incorporation efficiency) were calculated using the following two equations respectively:

\[
\text{Yield} (\%) = \frac{\text{weight of dry beads}}{\text{weight of drug and polymers}} \times 100
\]

\[
\text{Drug incorporation efficiency} (\%) = \frac{\text{Actual drug content in beads}}{\text{Amount of drug added}} \times 100
\]

Morphology and particle size analysis

The double-crosslinked hydrogel beads were characterized morphologically through scanning electron microscope (SEM; JEOL Model JSM - 6390LV, Tokyo, Japan). The hydrogel beads were coated with silver (as a conductive material) using a high–vacuum evaporator (Polaron system) under argon atmosphere by mounting the sample on metal grids. Particle size analysis of the hydrogel beads was performed using the Image J software (version 1.8.0_112).

Cytotoxicity studies

The cytotoxicity studies were performed using the HT-29 Human colon cancer cell line. Cells were seeded in 96-well plates at the densities of 1 × 10⁴ cells per well containing 0.1ml medium each and allowed to adhere to the plates by
incubating them for a period of 24 hours in a CO₂ incubator (Eppendorf, New Brunswick, Galaxy 170R, Germany). The incubator was maintained at 37°C and 95% humidity. Cell counts were performed by using the ELISA reader (Model 550, Bio-Rad Laboratories Inc., CA, USA). The cell culture medium was replaced with fresh medium containing the microbead formulation encapsulating 0.1 ml of 5-FU (25g/ml), or control samples (Portulaca mucilage and un-encapsulated 5-FU), and incubated at 37°C for 24 hrs. At the end of 24 hrs the medium in each well was replaced with 50μl of the MTT solution (5mg/ml in phosphate buffer saline) and the plate was incubated at 37°C for 4 hrs. In the next stage, 100μl of dimethyl sulfoxide (DMSO) was used to dissolve the formed formazan crystals in each well. The absorbance was recorded at 570nm filter using an immunosorbent assay (ELISA) plate reader (Lisa Plus, India). Cell viability percent was calculated using the following equation [38, 39]:

\[
\text{Percent cell viability} = \frac{\text{Absorbance of treated cells}}{\text{Absorbance of untreated (control cells)}} \times 100
\]

In vivo drug absorption assay

The efficacy of 5-FU encapsulated hydrogel beads for local release to colon site was assessed in a rat model by comparing with a control treatment. The protocols for in vivo study were approved by the Institutional Animal Ethics Committee (with the ethics committee approval number: SKNCP/IAEC/120/2017). Animals were fasted for 12 hours overnight before the studies and water was available ad libitum during the experiments. Rats were divided into three groups of six animals each. Group I was kept as control and rats were given normal saline, Group II received 5-FU immediate release (IR) formulations prepared by suspending the drug in 0.5% w/v sodium carboxymethyl cellulose (SCMC), and Group III received 5-FU-loaded microspheres. The dose of administered 5-FU was calculated according to surface area of rat’s colon (0.0023 x 500 x 7 = 8.05 mg) [40]. Animals were given corresponding formulations containing equivalent of 8.05mg of 5-FU by oral route. A 0.5ml blood sample was collected by retro-orbital bleeding under light anesthesia at 0, 2, 4, 8, 16, and 24 hours after administration of the drug-loaded hydrogel beads. The entire GI tract was then removed and mesenteric and fatty tissues were separated. The GI tract was separated into stomach, small intestine, cecum, and colon. These organs were homogenized by a microtissue homogenizer (Remi Ltd., Mumbai, India) using phosphate buffer (pH 7.4) premixed with 1.5ml of acetonitrile and incubated for 45min. The samples were then centrifuged, supernatants collected and were appropriately diluted with the mobile phase, and the 5-FU content was determined by the HPLC method as described in References [41, 42].

Statistical Analysis

The Student t-test was used to perform statistical analysis and to determine the statistical significance. A value of P less than 0.05 was considered statistically significant.

Results and Discussion

Currently, 5-FU delivery to patients is achieved mainly by the intravenous administration. However, it has been shown that the drug shows erratic absorption, inconsistent dosing and some side effects following i.v. administration [5,6]. With respect of addressing colon cancer, various efforts have been made to target drugs to colon using alternative routes of administration, including oral route, and employing different types of drug delivery systems as explained in the Introduction. The wide pH range of gastrointestinal tract causes difficulty for the delivery of drug to the colon and the hostile environment of the stomach causes polysaccharide-based delivery systems to disintegrate before reaching the colon.

Multiparticulate drug delivery systems of 5-FU based on dual concepts, namely a pH-dependent and microflora-activated system, have been shown to be useful in vitro [43] while adequate pharmacokinetic and pharmacodynamics of a 5-FU colon-specific formulation is lacking. Consequently, in the present research Portulaca is used as a natural oral delivery matrix for targeting 5-FU...
to the colon and the safety and efficacy of the formulation was assessed in vitro and in vivo.

**Percentage yield**

The percentage yield of extraction of the mucilage from the Portulaca oleracea (Purslane) leaves was $8.4 \pm 1.7\%$ w/w. Furthermore, a high percentage yield of manufacturing hydrogel beads employing the Portulaca mucilage and other ingredients was obtained (i.e. $82\%$ w/w).

**Encapsulation efficiency**

A high value for 5-FU encapsulation efficiency was attained ($78\%$ w/w). This was an expected outcome due to the high level of crosslinking of the hydrophilic polymer matrix. This value is in line with the encapsulation efficiencies of 5-FU reported for an alginate-based hydrogel composite [44], and higher than the recently reported drug carrier technology Tocosome (i.e. 43-71%) obtained by Mozafari and colleagues [17]. However, the drug encapsulation efficiency obtained in the present study is lower than the value obtained for a nanoliposomal formulation of 5-FU (up to 97%) as reported by Elmeshad and coworkers [16].

**Morphology and particle size studies**

For morphological studies and size measurement of the Portulaca mucilage hydrogel beads, the scanning electron microscopy (SEM) technique was employed. SEM is one of the well-established and widely applied techniques for the analysis of shape, surface structure and size of different drug carriers [45,46]. Results of SEM analysis revealed spherical beads with a coarse surface morphology. Representative SEM images of the hydrogel beads are shown in Figure 1. The SEM images depict rough surface with flakes and wrinkles. These flakes and wrinkles might be caused by cross-linking of the polymeric network or partial collapse of the hydrogel beads during sample preparation for SEM analysis [47]. The particle size values of the microbeads prepared in the present study were in the range of 930 to 977μm.

---

**Figure 1:** (A) Beads made of alginate depicted as a control; (B) Microspheres made of Portulaca-alginate-epichlorohydrin (double crosslinked hydrogel beads); and: (C) Three dimensional representation of scanning electron micrograph depicting the overall shape and surface morphology of Portulaca-alginate-epichlorohydrin double crosslinked hydrogel beads encapsulating the anticancer agent 5-fluorouracil.
Cytotoxicity studies

In-vitro cytotoxicity of hydrogel beads encapsulating 5-FU, as well as the Portulaca mucilage and un-encapsulated 5-FU solution was studied using HT-29 human colon cancer cell line by the MTT colorimetric assay. Cell viability percent for each sample was calculated and the results are depicted in Figure 2. Survival rates for the un-encapsulated drug was found to be lower compared to the Portulaca mucilage and drug-loaded hydrogel beads. The cytotoxicity trend of 5-FU was concentration dependent in the range tested. Results showed that Portulaca mucilage and microbead-encapsulated 5-FU formulations were less cytotoxic towards the cell line tested compared to the un-encapsulated drug. It is known that Portulaca is a plant with unique anticancer properties [34]. Therefore, combination of the extract of this plant with 5-FU provides a synergistic mechanism of action, as attested by the data obtained in this study (Figure 2).

In vivo drug distribution study

The pharmacokinetic parameters of the anticancer drug, encapsulated and un-encapsulated, are shown in Table 1. The un-encapsulated drug was prepared by dissolving 5-FU in carboxymethyl cellulose and designated as immediate release (IR) formulation, as explained under the Materials and Methods section. The plasma drug concentration / time profiles of the two formulations are entirely different. The maximum drug concentration in plasma (C_{max}) was noticeably different for the two formulations, i.e. 8.96 μg/ml vs. 90.1 μg/ml for the hydrogel beads and IR formulations, respectively. Time to reach maximum drug concentration in plasma (i.e. T_{max}) was 16 ± 1.2h for the hydrogel beads, which was considerably higher than the T_{max} for the IR formulation (i.e. 1.2 ± 0.81h). The mean residence time (MRT) was 14.08 ± 2.34h for the hydrogel beads, which was 4.26 times higher than that of the IR formulation (3.30 ± 0.23h). All of the values obtained for the pharmacokinetic parameters (C_{max}, T_{max}, and MRT) for the two formulations were significantly different (P < 0.001).
Results also showed that drug absorption was sustained as indicated by a high $T_{\text{max}}$ value (Table 1). This finding suggests that the hydrogel beads, prepared by dual crosslinking of Portulaca mucilage, effectively prevent drug release in the upper part of the GI tract. Enzymatic degradation of the Portulaca polysaccharides by the enzymes of the colonic microflora is a slow process, which usually takes 12h. The encapsulated 5-FU formulation showed 16h drug release due to slow degradation of the polysaccharides. The IR formulation (un-encapsulated drug) showed the highest Cmax value that is because most of the 5-FU was absorbed in the upper part of the GI tract. The higher value of $T_{\text{max}}$ obtained for the encapsulated drug indicates low systemic toxicity since less quantity of the drug is available systemically for interaction with non-target sites. Consequently, encapsulation of the anticancer agent results in increasing the safety and efficacy index of the formulated hydrogel beads. The extended MRT of the hydrogel beads indicates that the drug was slowly and steadily released in the colon. These findings are in good agreement with the previously reported studies [48, 49].

Table 1: Pharmacokinetic parameters of encapsulated 5-FU in the dual crosslinked epichlorohydrin / Portulaca mucilage hydrogel beads and the un-encapsulated (immediate release, IR) drug formulation in rat.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>5-FU microspheres</th>
<th>IR formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ (μg/ml)</td>
<td>8.96</td>
<td>90.1</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (h)</td>
<td>16</td>
<td>1.2</td>
</tr>
<tr>
<td>AUC (μg/ml/h)</td>
<td>117.78</td>
<td>125.5</td>
</tr>
<tr>
<td>Mean residence time (h)</td>
<td>14</td>
<td>3.33</td>
</tr>
<tr>
<td>Relative bioavailability (%)</td>
<td>93.6</td>
<td>100</td>
</tr>
</tbody>
</table>

$C_{\text{max}}$: maximum plasma concentration. $T_{\text{max}}$: time to $C_{\text{max}}$. AUC: area under-the-curve of the plasma concentration vs. time (0–24h).

Figure 3: Drug concentration versus time profiles of encapsulated and free 5-FU in: (A) plasma; (B) stomach tissue homogenate; and (C) intestinal tissue homogenate after oral administration of colon-specific microspheres in Wistar rats. The immediate release (IR) formulation of 5-FU was prepared by suspending the drug in 0.5% w/v sodium carboxymethylcellulose. Data are mean± s.d. (n=3).
Organ distribution study

The organ distribution studies of the encapsulated 5-FU were carried out to evaluate the target specificity of the formulation in an animal model. Results indicated that maximum concentration of the un-encapsulated 5-FU (i.e., 94.5 ± 5.4%) was observed after 2h in stomach when given orally. In the following hours, much less drug reached the small intestine, and afterwards no 5-FU was found in the colon. However, Portulaca mucilage-based hydrogel beads were observed and found intact in the upper part of the GI tract. Approximately 15.3% of the total encapsulated 5-FU was released during its passage through the upper GI tract. After 8–10h, the maximum release of the encapsulated 5-FU was observed in the colon and a very insignificant amount of the drug was detected in the stomach and small intestine (Figure 3). Results attest that the formulated hydrogel beads are ideal systems for colon-specific drug delivery (Figure 4).

Conclusion

The anticancer drug 5-FU is a therapeutic agent with a very short half-life and significant side effects particularly when given in conventional dosage forms. In an attempt to improve the therapeutic efficacy and safety of the drug, a novel hydrogel bead formulation was developed for localized delivery of 5-FU to the colon. The drug delivery system was prepared by dual crosslinking of Portulaca mucilage using epichlorohydrin. The formulated microspheres were analyzed for their in vitro and in vivo safety and efficacy. The pharmacokinetic study revealed enhanced bioavailability of the therapeutic agent, while the GI distribution studies indicated localized drug concentration in the colon. The novel dual crosslinked Portulaca microspheres prepared in this study are proven to be a promising oral delivery system to combat colon cancer. Further studies...
are required to establish long-term stability and clinical efficacy of the formulation.

Acknowledgements: The authors are thankful to the Sinhgad Technical Education Society and Dr. S. D. Sawant, Principal, Smt. Kashibai Navale College of Pharmacy, Kondhwa, Pune and Dr. Prabhakar Kore Basic Science Research Centre, KLE University, Belgaum for providing required research facilities.

Animal handling ethics: The animal experimental protocols performed in this study were approved by the Institutional Ethical Committee for Care and Use of Laboratory Animals and they were handled according to the code of ethics in research, training, and testing of drugs. The ethics committee approval number is: SKNCP/IAEC/120/2017.

Conflict of interest: Authors state no conflict of interest.

References


